cro leadership awards 2014 banner

What Are The Awards?

Companies achieving top 20 percentile perception scores in the areas of Innovation, Productivity, Quality, Regulatory, and Reliability will be recognized for their achievement.


2014 CRO Leadership Award Winners


The Philosophy Of The Awards

Life Science Leader’s pharmaceutical and biopharmaceutical subscribers have told us about their struggles in efficiently vetting potential CRO partners. In response to this input Life Science Leader developed the CRO Leadership Awards, based on the industry-leading research conducted by Nice Insight. The awards incorporate the common filters used by pharma companies to vet CROs, with the added filter of peer feedback. This will help pharma companies focus on potential CRO partners that can handle their projects and are considered reputable in the industry.

Unlike other industry awards, which are given based on a subjective voting or nomination process, the only votes that count toward the CRO Leadership Awards are those of the pharmaceutical and biopharmaceutical companies using CRO services.

View the digital edition to Life Science Leaders's CRO supplement.


  • A CRO Awards Program With No Strings Attached

    At Life Science Leader magazine, it is our pleasure to announce the third annual 2014 CRO Leadership Awards winners. Unlike other award programs where there can be only one winner per category, our awards list all the CROs that scored in the top 20 percent for the following categories — quality, reliability, innovation, productivity, and regulatory. Furthermore, there is not an overall CRO leadership award winner. Let me explain why we’ve taken this approach.

  • The Future Of Clinical Trials In An Outsourced Model

    Throughout human history people have held a fascination with trying to predict the future, employing a variety of tools — crystal balls, palm readings, tarot cards, or my personal favorite, the Magic 8 Ball. Scientists typically use data when forecasting the future.

  • Building Strategic Partnerships With CROs For Businesses Of All Sizes

    As strategic partnerships become a greater focus for both sponsors and CROs, there are some concerns that these types of relationships will negatively impact the industry by causing a greater imbalance in an already perceived to be unbalanced playing field. These worries tend to come from, and impact, the smaller players in the market. Smaller clients of big CROs worry their projects will receive significantly less attention than the CROs’ strategic partnerships. Small CROs worry there won’t be a place for them in the industry, because they do not have as broad an offering and are unable to provide support across the entire development cycle.

  • How To Improve Clinical Trials – Some Good Old-Fashioned Wisdom

    Intel cofounder Gordon Moore predicted in 1965 that the number of transistors on an integrated circuit would double approximately every two years. What came to be known as Moore’s Law has basically held true ever since.

  • Extracting the Value From Outsourcing By Applying Best Outsourcing Practices

    By its very nature, outsourcing can be a double-edged sword. On one hand you could consider outsourcing as an approach to increase your geographic reach, retain organizational flexibility or a smaller footprint, or achieve some other business goal.

  • Biopharma’s Needs And Focus Of Small Sponsors

    In this day and age of preferred service provider relationships and/or functional service providers, small pharmaceutical and biotechnology companies present a unique challenge to service providers vying for their business. The resource constraints (both money and people) and time lines are critical, given a narrow or single product development pipeline, little to no revenue stream, and a hyperfocused management team. While these issues may not be unique to small companies, oftentimes the viability of a project, and possibly the company, may lie within two critical aspects — the people and on-time delivery of the project.

  • The Clinical Research Crystal Ball: Looking At The Future

    In the life sciences industry, we are always hyper-vigilant about all of the risks involved in product development. Therefore, our “cuttingedge” approaches seem not quite as innovative as other high-tech industries. The time has come for a few key best practices that add efficiency and cost-effectiveness, something the clinical development world desperately needs. In order to confirm my theories, I queried a number of executivelevel professional colleagues in pharmaceutical and biotechnology companies, who shared their views off the record. I analyzed my queries and compiled the results into a cohesive discussion below. To add a note of practicality to each, I’ll suggest considerations for those who want to make it happen in the present and look toward the future.

  • Impact Of Strategic Outsourcing On QA Oversight By Sponsor Companies

    Recently, we have been observing a change in the approach to outsourcing — more midsize and large biopharmaceutical companies are shifting to a strategic outsourcing model. Strategic outsourcing generally means assigning work to one or a maximum of two preferred (strategic) partners.